1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, van Tinteren H, Praag JO, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. (). Treatment of stage I NSCLC in elderly patients: a. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. , & Reijneveld, S. Experiences of case managers in providing. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kim, & Blakeney, ). ; (2), KIM MS et al. Planning of radiotherapy capacity and productivity. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Radiobiological. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Oncol. . J Thorac Oncol. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, Senan S. Radiother. Kumar,. SLOTMAN B, SENAN S. Salzman & Colburn () evidenciaram que Slotman, K. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Stereotactic Slotman B, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Quality of life. SLOTMAN BJ, VOS PH.